Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DTC Ads Remain Controversial Despite Positive Study Results, PhRMA Says

Executive Summary

The Pharmaceutical Research & Manufacturers of America is prepared to use the results of recent direct-to-consumer advertising studies to respond to critics of the marketing practice

You may also be interested in...



GSK Selling Direct To Canadian Pharmacies, Auditing Orders To Curb Imports

GlaxoSmithKline is selling its products direct to pharmacies in Canada that are suspected by the company of selling to consumers in the U.S

GPhA Objection To Generic Drug Rule Could Backfire, FDA Counsel Troy Warns

The generic industry should consider carefully any attempt to derail FDA's regulatory approach to Waxman/Hatch reform, agency Chief Counsel Daniel Troy told the Generic Pharmaceutical Association

FDA Readies Report On DTC, Says Physician Survey Supports Current Policy

FDA expects to publish a report on its 1997 direct-to-consumer broadcast advertising policy this spring

Related Content

UsernamePublicRestriction

Register

PS041346

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel